|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Licensing and collaboration revenue | |||||
| Operating expenses and income | |||||
| Research and development expenses | |||||
| Third parties | |||||
| Related parties | |||||
| Administrative expenses | |||||
| Other operating income, net | |||||
| Loss from operations | |||||
| Interest and investment income | |||||
| Interest expense | |||||
| Other income, net | |||||
| Foreign exchange gain (loss), net | |||||
| Change in fair value of warrant liabilities | |||||
| Loss before income tax | |||||
| Income tax benefit (expense) | |||||
| Net loss attributable to Adagene Inc.'s shareholders | |||||
| Accretion of convertible redeemable preferred shares to redemption value | |||||
| Net loss attributable to ordinary shareholders | |||||
| Weighted average number of ordinary shares used in per share calculation: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
| Net loss per ordinary share | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Other comprehensive income (loss) | |||||
| Foreign currency translation adjustments, net of nil tax | |||||
| Total comprehensive loss attributable to Adagene Inc.'s shareholders |
Loading...
